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Summary
Familial orthostatic hypotensive disorder is character-
ized by light-headedness on standing, which may worsen
to syncope, palpitations, and blue-purple ankle discol-
oration, and is accompanied by a marked decrease in
systolic blood pressure, an increase in diastolic pressure,
and tachycardia, all of which resolve when supine. We
ascertained three families in which this disorder is in-
herited as an autosomal dominant trait with reduced
penetrance. A genomewide scan was conducted in the
two largest families, and three regions with multipoint
LOD scores 11.5 were identified. Follow-up of these
regions with additional markers in all three families
yielded significant evidence of linkage at chromosome
18q. A maximum multipoint LOD score of 3.21 in the
three families was observed at D18S1367, although the
smallest family had negative LOD scores in the entire
region. There was significant evidence of linkage in the
presence of heterogeneity at 18q, with a maximum LOD
score of 3.92 at D18S1367 in the two linked families.
Identification of the gene responsible for orthostatic hy-
potensive disorder in these families may advance un-
derstanding of the general regulatory pathways involved
in the continuum, from hypotension to hypertension, of
blood pressure.
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Introduction
The regulation of blood pressure (BP) is a multifactorial
process that involves numerous biological pathways that
maintain a constant equilibrium between vasoconstrict-
ing and vasodilating factors. Arterial hypertension is the
result of chronic tilting of this balance toward vasocon-
striction, owing to an interplay of genetic and environ-
mental factors, and, consequently, results in an increase
in peripheral resistance. Hypotension is usually an acute
clinical syndrome that follows loss of blood volume,
endocrine or vasomotor disorders, or cardiac (rhythm
or function) disturbances. Hypotension can also be a
chronic condition that stems from autonomic dysfunc-
tion and is either idiopathic or secondary to a variety
of systemic diseases, such as diabetes mellitus or amy-
loidosis (Robertson et al. 1992). In rare cases, hypoten-
sion is part of the constellation of abnormalities that
define a variety of familial disorders that are a result of
specific genetic defects, such as the monoamine oxidase
deficiency owing to an X-chromosome deletion (Sims et
al. 1989). The majority of studies to identify genes that
influence BP have focused on hypertensive individuals,
but the isolation of genes in familial disorders charac-
terized by hypotension is equally important to the dis-
section of the process of BP regulation.
In 1972, Streeten and colleagues reported a novel fa-
milial orthostatic hypotensive syndrome (MIM 143850;
Streeten et al. 1972). Five patients from four families
were described as having orthostatic intolerance that
ranged in severity from light-headedness to syncope, ow-
ing to a profound fall in systolic BP (SBP) and a rise in
diastolic BP, that in many cases was associated with
flushing, palpitations, leg edema, and/or varying pur-
plish discoloration. The original clinical evaluation ruled
out known causes of orthostatic hypotension and at-
tributed the symptoms to hyperbradykininism. All pa-
tients had affected first-degree relatives, indicating a ge-
netic basis for the disorder.
Extended pedigree information and DNA samples
were obtained for three of the families in the original
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report, and linkage analyses were conducted. We report
here the identification of a chromosomal region on 18q,
which demonstrates significant evidence of linkage to the
disorder in these families.
Families and Methods
Families
Members of the four families from which the five pa-
tients described by Streeten et al. (1972) originated were
contacted directly and were asked about the presence of
symptoms, including dizziness and/or purple discolora-
tion of legs on standing, their use of medication for BP
regulation, and their ability to engage in physical activ-
ity. Information on minor children was provided by a
parent. Medical records from prior exams (by D.H.P.S.)
were available for the majority of patients who self-
reported an affected status. In addition, local physicians
were questioned regarding their patients’ symptoms, BP
response to orthostasis, and treatment. One family was
excluded from this study because its current physician
observed no important changes in BP or in heart rate
during orthostasis, despite the presence of other symp-
toms. For the remaining three families, DNA samples
were obtained from 38 individuals, including 14 affected
individuals and 1 obligate carrier (fig. 1). Clinical mea-
surements for patients are shown in table 1. For linkage
analysis, individuals were classified as affected if an ex-
cessive orthostatic drop in SBP (118 mm/Hg) and rise
in heart rate were observed. Individuals for whom de-
tailed clinical information was not available were clas-
sified as affected if they reported orthostatic symptoms.
Individual 5066 is not currently being treated and was
initially reported as unaffected. Reevaluation of his clin-
ical status revealed that he experiences light-headedness
on standing; however, he declines treatment. In this anal-
ysis he is classified as affected. Individual 5052 experi-
ences a significant drop in SBP on standing and is, there-
fore, classified as affected, but she experiences no
symptoms. She is a high-level athlete, and it is possible
that her physical condition enables her to compensate
for her BP changes. A single nonpenetrant individual
(5176) with an affected parent and offspring was
observed.
Genotyping
Peripheral blood was obtained from the subjects in
accordance with institutional guidelines for human sub-
jects, and DNA was isolated from blood leukocytes by
the proteinase K-SDS method (Sambrook et al. 1989).
A series of 200 highly polymorphic tri- and tetranucle-
otide microsatellite markers, spaced an average of 20
cM apart, were typed in the two largest families (Shef-
field et al. 1995). To make efficient use of laboratory
resources, the third family was typed only for markers
in the regions of interest that had been identified in the
two larger families. A standard amplification reaction
(10 ml; Saiki et al. 1988) was performed, with 40 ng
genomic DNA and 1.0 pmol of each primer. Cycling
parameters consisted of 95C for 5 min, followed by 35
cycles of 94C for 1 min, 60C for 30 s, and 72C for
30 s. Prior to amplification, one primer was end-labeled
with 32P and polynucleotide kinase (New England Biol-
abs), in order for the amplification product to be visible
by autoradiography after application to a standard se-
quencing gel.
Linkage Analysis
For initial screening, multipoint parametric linkage
was assessed using GENEHUNTER (Kruglyak et al.
1996) in the two families (BU134 and BU233) in which
the genome scan was performed. An autosomal domi-
nant mode of transmission with a reduced penetrance
of 80% was assumed. Penetrance was not modeled as
age dependent, because symptoms typically appear in
childhood, and all unaffected children included in the
analysis are older than the youngest onset age. Marker-
allele frequencies were assumed to be equal, but this
assumption had little influence on the linkage results,
because nearly complete genotype information was
available for the founders. Given the number of indi-
viduals in the largest family and computational limita-
tions, two unaffected individuals (5067 and 5069) could
not be included in the GENEHUNTER analysis. Since
the sharing of alleles among affected individuals is most
critical for identifying linkages in a reduced-penetrance
model, no linked regions would be missed by exclusion
of these two unaffected persons. The genetic information
provided by them could have small effects on the LOD
scores, however. To maximize the amount of genetic in-
formation extracted from the largest family, regions that
yielded an aggregate LOD score x1.5 were reanalyzed
by VITESSE (O’Connell and Weeks 1995). This enabled
the inclusion of all individuals when a limited number
of markers in a specific chromosomal region was se-
lected. Positive regions were further examined by the
typing of additional markers in all three families. After
completion of the genome screen, a DNA sample was
obtained on an additional affected individual (7051).
Therefore, LOD scores computed on the basis of the
follow-up of positive regions reflect an additional mei-
otic event, as well as increased marker information.
Model assumptions for VITESSE analyses were identical
to those used in GENEHUNTER. The possibility of link-
age heterogeneity was considered by performance of the
admixture test, implemented in the program HOMOG
(Ott 1991).
Figure 1 Pedigrees of three families with BP-regulation disorder. Identification numbers, which indicate that a DNA sample was obtained, are given under the symbols. Onset age (affected
individuals) or current age (unaffected individuals) are shown. Values in parentheses are age at diagnosis for affected individuals for whom precise onset age could not be established.
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Table 1
Clinical Information Obtained from Affected and Unaffected
Family Members
FAMILY
AND
INDIVIDUAL
BLOOD PRES-
SURE(mm/Hg)
HEART RATE
(bpm)a
CLINICAL
DIAGNOSISbLying Standing Lying Standing
BU133:
5050 124/90 98/88 88 144 A
5051 124/50 122/84 64 84 N
5052 114/68 94/70 80 104 A
5058 108/58 90/82 72 104 A
5060 126/68 64/60 80 156 A
BU134:
5063 118/70 100/74 54 72 A
5064 114/74 86/74 72 112 A
5065 136/70 102/90 68 108 A
5068 116/58 80/70 88 132 A
BU233:
5177 154/86 128/100 76 116 A
5178 100/60 104/64 60 68 N
5182 118/76 80/74 76 164 A
5185 114/64 104/76 60 72 N
5186 90/52 90/60 72 88 N
5187 106/56 106/64 72 96 N
7051 115/72 84/76 70 108 A
abpm  beats per minute
bA  affected; N  unaffected.
Figure 2 Multipoint linkage maps obtained by the program
VITESSE, with the most informative markers on 18q. The markers
and their relative distance are shown on the x-axis. D18S858 was
arbitrarily placed at 0 cM.
Results
Multipoint parametric LOD-score analysis excluded
1,512 cM by the conservative criterion of a LOD score
!2. An additional 705 cM had negative evidence for
linkage (LOD score !1). Three regions (13p, 3q, and
18q) showed suggestive evidence of linkage, on the basis
of the criterion of an aggregate LOD score 11.5. Re-
analysis of the positive regions, conducted by use of the
VITESSE program, yielded a maximummultipoint LOD
score (Zmax) of 2.19 at 13p, 2.21 at 3q, and 3.5 at 18q.
These locations were investigated further by typing ad-
ditional markers in all three families.
Saturation of the 18q region with additional markers
resulted in an aggregate LOD score of 3.21 in the three
families. Haplotype sharing within each family was ob-
served for all affected individuals and for obligate car-
riers in the three families. However, in BU133, three
unaffected persons share the complete putative disease
haplotype, resulting in negative LOD scores throughout
the region (fig. 2). The admixture test as implemented
in the program HOMOG was used to test for evidence
of locus heterogeneity (Ott 1991). Evidence of linkage
to 18q in the presence of heterogeneity was obtained
( ; ), and the likelihood ratio L2/2x  15.16 P  .0003(2)
L0 (1,961:1) approached the suggested criterion of
2,000:1 (Terwilliger and Ott 1994). The conditional
probability of linkage was high for BU134 (.99
[.98–1.0]) and for BU233 (.98 [.08–1.00]) and low for
BU133 (.43 [.02–1.00]). In the linked families (BU233
and BU134), the multipoint Zmax was 3.92. Recombi-
nations in two affected individuals place the disease gene
within a 25-cM region, between D18S858 and D18S541
(fig. 3).
A multipoint Zmax of 2.44 was obtained at the chro-
mosome 13p region in the three families. The strongest
evidence for linkage was observed in BU134 (Z max
at D13S221), which does not reach the criterion2.14
for significance. Follow-up of the 3q region yielded a
maximum multipoint LOD score of 1.71, between
D3S2398 and D3S1754, with the majority of evidence
for linkage observed in BU134 ( at D3S2455).Z  2.3max
The admixture test provided weak evidence for linkage
in the presence of heterogeneity ( ; ),2x  8.8 P  .006(2)
with odds for linkage and heterogeneity of 83:1. It is
unlikely, therefore, that a gene at this location accounts
for disease susceptibility in these families.
Discussion
The three families displayed a broad spectrum of se-
verity of phenotype. The most severely affected individ-
uals frequently experience light-headedness and fainting
on standing and are unable to perform daily tasks unless
treated. In contrast, two mildly affected individuals
(5066 and 5068) experience orthostatic light-headedness
but are not receiving treatment for the disorder. One
individual (5176) is an obligate carrier of the disease
gene but experiences no symptoms and has normal BP
verified by yearly exams. Uncertainty about themutation
status of apparently unaffected individuals was allowed
for in the linkage analysis by the use of a reduced pen-
etrance function. A more conservative approach con-
siders information on haplotype sharing in affected
individuals only. The nonparametric-linkage statistic
computed by GENEHUNTER is a nonparametric ap-
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Figure 3 Haplotypes of affected individuals that define the pu-
tative disease-gene location for 18q. Blackened squares indicate regions
of allele sharing among affected individuals; unblackened squares rep-
resent recombinant regions.
proach that evaluates allele sharing among affected rel-
ative pairs. In the initial genome screen, evidence for
linkage based on the maximum NPL statistic (NPLmax)
was nearly identical for the three positive regions (3q,
[ ]; 13p, [NPL  3.95 P  .0078 NPL  4.48 P max max
]; and 18q, [ ]). The few-.0048 NPL  4.17 P  .0078max
est inferred recombinants (unaffected individuals car-
rying the putative disease haplotype), however, were ob-
served at the chromosome 18 location in the two linked
families. Parametric LOD-score analysis with the more
liberal penetrance assumption of 80% provided the
strongest evidence of linkage to the chromosome 18q
location in the two largest families.
Quantitative-trait loci (QTLs) for BP have been
mapped to human chromosomes 17q and 8p22 (Wu et
al. 1996; Julier et al. 1997), among others. To our
knowledge, the chromosomal regions identified in the
current study have not been implicated by QTL linkage
studies in human populations or in studies using animal
models.
There are several serpin (serine protease inhibitor)
genes, including those for plasminogen-activator inhib-
itor-2 (PAI2), maspin, and bomapin, in the chromosome
18 candidate region (Schneider et al. 1995). Although
none of these candidate genes have been implicated di-
rectly in BP regulation, it remains possible that they pos-
sess functions not yet described. Proteases are involved
in the formation and degradation of various vasoactive
peptides. The inhibition of proteases, through the use of
ACE inhibitors, is the basis of one successful therapeutic
approach to the control of BP. Therefore, serpins may
be an important class of genes for BP regulation, and
those located at 18q should be considered as candidates
for orthostatic hypotensive disorder. The PAI2 gene was
scanned for mutations by use of SSCP. Preliminary ex-
amination provided no evidence of mutation in the PAI2
gene in affected individuals in these families.
The original report on these families ruled out known
causes of orthostasis and established a common finding
of hyperbradykininism, based on high levels of plasma
bradykinin and low plasma bradykininase-I concentra-
tions (Streeten et al. 1972). In the quarter century since
that report, however, measurements of plasma brady-
kinin from these patients have given apparently conflict-
ing results, which are actually consistent with the fact
that plasma bradykininase concentration can be vari-
able, as described (Streeten et al. 1972). The present
study has found no evidence of linkage to regions con-
taining hyperbradykininism-candidate genes, such as the
bradykinin receptors B1 and B2 (14q32.1-q32.2) and
kallikrein (19q13.2-q13.4). It is interesting to note that
the kininogen gene (3q27) is located in the chromosome
3 region that yields a positive LOD score; however, ev-
idence of linkage to this location is weak compared with
evidence for linkage to chromosome 18. The possibility
that a genetic mechanism for deficient bradykininase
synthesis might be responsible for this syndrome is still
a tenable hypothesis that remains to be excluded.
Identification of the gene that causes familial ortho-
static hypotension disorder will enable genetic testing
and could potentially lead to improved treatment for
individuals with this condition. Discovery of the mu-
tations in these families, however, may impact more
broadly by shedding light on the process of BP regula-
tion. Hypertension, which affects ∼20% of the popu-
lation and is associated with morbidity from stroke,
heart attack, and renal disease, can be considered the
mirror image of hypotension. This relationship has been
proven in the identification of mutations in the epithelial
sodium-channel gene, which result in Mendelian forms
of both hypotension (pseudohypoaldosteronism type 1;
Chang et al. 1996) and hypertension (Liddle syndrome;
Hansson et al. 1995). Investigation of candidate genes
on 18q may provide additional insights into the role of
genetics in BP regulation.
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